RNS Number : 3892R
Destiny Pharma PLC
28 February 2023
 

28 February 2023

Destiny Pharma plc

Posting of Circular and Notice of General Meeting

Destiny Pharma plc (AIM: DEST) (the "Company" or "Destiny Pharma"), is pleased to confirm that, further to the announcement of 24 February 2023, the shareholder circular (the "Circular") providing further details of the Placing, Subscription and the Open Offer and notice of General Meeting has been posted to shareholders today.

The Circular contains a Notice of General Meeting to be held at the offices of Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ on 16 March 2023 at 2.00 p.m. (the "General Meeting").  Please note that the time of the General Meeting has changed from that announced on 24 February 2023.

A copy of the Circular, Open Offer Application Form and Form of Proxy will shortly be available from the Company's website (www.destinypharma.com).

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS



2023

Announcement of the Placing, the Open Offer and the Subscription

24 February

Record Date for entitlements under the Open Offer

Close of business on 23 February

Ex-entitlement Date for the Open Offer

8.00 a.m. on 27 February

Posting of the Circular (including the Notice of General Meeting), the Form of Proxy and, to Qualifying Non-CREST Shareholders, the Application Form

28 February

Basic Entitlements and Excess Entitlements credited to stock accounts of Qualifying CREST Shareholders

As soon as possible on 1 March

First Admission and commencement of dealings in the Placing Shares and the Subscription Shares on AIM

8.00 a.m. on 1 March

First Placing Shares in uncertificated form pursuant to First Admission expected to be credited to accounts in CREST

As soon as possible after 8.00 a.m. on 1 March

Recommended latest time and date for requesting withdrawal of Basic Entitlements and Excess Entitlements from CREST

4.30 p.m. on 9 March

Latest time and date for depositing Basic Entitlements and Excess Entitlements into CREST

3.00 p.m. on 10 March

Latest time and date for splitting Application Forms (to satisfy bona fide market claims only)

3.00 p.m. on 13 March

Latest time and date for receipt of completed Application Forms and payment in full under the Open Offer or settlement of relevant CREST instructions (as appropriate)

11.00 a.m. on 15 March

Announcement of the results of the Open Offer

15 March

Latest time and date for receipt of CREST proxy instructions and registration of online votes from Shareholders for General Meeting

2.00 p.m. on 14 March

Latest time and date for receipt of Forms of Proxy

2.00 p.m. on 14 March

General Meeting

2.00 p.m. on 16 March

Announcement of the results of the General Meeting

16 March

Second Admission and commencement of dealings in the Committed Open Offer Shares on AIM

8.00 a.m. on 17 March

Committed Open Offer Shares in uncertificated form pursuant to Second Admission expected to be credited to accounts in CREST (uncertificated holders only)

As soon as possible after 8.00 a.m. on 17 March

Dispatch of definitive share certificates for the New Shares in certificated form

Within 5 business days of
First Admission, or Second

Admission, where applicable

 

Each of the times and dates above refer to London time and are subject to change at the absolute discretion of the Company, finnCap and Shore Capital. Any such change will be notified to Shareholders by an announcement through a Regulatory Information Service. Certain of the events in the above timetable are conditional upon, inter alia, the approval of the Resolutions to be proposed at the General Meeting.

 

 

For further information, please contact: 

 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

+44 (0)1273 704 440 

pressoffice@destinypharma.com 

 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0)20 7220 0500

 

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

DestinyPharma@optimumcomms.com 

 

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

Stern IR - US

Janhavi Mohite

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGKZGZZKRDGFZM